Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
This article was originally published in The Tan Sheet
Executive Summary
Perrigo further delays plans for a generic version of Reckitt Benckiser's Mucinex, saying the product it once touted as a 2010 highlight may not emerge even during the firm's fiscal 2011
You may also be interested in...
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Perrigo stokes momentum behind already healthy sales growth with significant steps in separate areas: a green light for regulatory compliance at its main manufacturing plant, and the launch of its generic OTC versions of Sanofi-Aventis' Allegra.
Mucinex Patent Ruling Breathes Life Into Watson And Perrigo ANDAs
Watson Pharmaceuticals' success against Reckitt Benckiser's Mucinex patent infringement suit could clear a path for Mucinex equivalents to launch in the first half of 2011.
Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"
Perrigo is "poised for some significant growth" with $180 million in new product sales expected in the firm's current fiscal year, according to President and CEO Joseph Papa.